Cic edizioni internazionali
Functional Neurology

Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study

Original Article, 259 - 264
doi: 10.11138/FNeur/2013.28.4.259
Tag this article
Abstract
Enhanced HTML Full text PDF
Zolpidem has been reported as an “awakening drug” in some patients with disorders of consciousness (DOC).
We here present the results of a prospective openlabel study in chronic DOC patients. Sixty patients (35±15 years; 18 females; mean time since insult ± SD: 4±5.5 years; 31 with traumatic etiology) with a diagnosis of vegetative state/unresponsive wakefulness syndrome (n=28) or minimally conscious state (n=32) were behaviorally assessed using the Coma Recovery Scale-Revised (CRS-R) before and one hour after administration of 10 mg of zolpidem. At the group level, the diagnosis did not change after intake of zolpidem (p=0.10) and CRS-R total scores decreased (p=0.01). Twelve patients (20%) showed improved behaviors and/or CRS-R total scores after zolpidem administration but in only one patient was the diagnosis after zolpidem intake found to show a significant improvement (functional object use), which suggested a change of diagnosis. However, in this patient, a double-blind placebo-controlled trial was performed in order to better specify the effects of zolpidem, but the patient, on this trial, failed to show any clinical improvements.
The present open-label study therefore failed to show any clinically significant improvement (i.e., change of Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study diagnosis) in any of the 60 studied chronic DOC patients

Vol. XXXII (No. 1) 2017 January/March

  1. Back to the future: 30th anniversary of deep brain stimulation for Parkinson’s disease
    Pozzi N.G., Pacchetti C.
    doi: 10.11138/FNeur/2017.32.1.005
  2. Recent advances in the molecular genetics of frontotemporal lobar degeneration
    Rainero I., Rubino E., Michelerio A., D'Agata F., Gentile S., Pinessi L.
    doi: 10.11138/FNeur/2017.32.1.007
  3. The coefficient of friction in Parkinson’s disease gait
    Kleiner A., Galli M., Franceschini M., De Pandis M.F., Stocchi F., Albertini G., de Barros R.M.L.
    doi: 10.11138/FNeur/2017.32.1.017
  4. Reappraisal of the F/M amplitude ratio in carpal tunnel syndrome
    Ginanneschi F., Mondelli M., Aretini A., Rossi A
    doi: 10.11138/FNeur/2017.32.1.023
  5. Gait analysis and clinical correlations in early Parkinson’s disease
    Pistacchi M., Gioulis M., Sanson F., De Giovannini E., Filippi G., Rossetto F., Zambito Marsala S.
    doi: 10.11138/FNeur/2017.32.1.028
  6. Vitamin D in amyotrophic lateral sclerosis
    Libonati L., Onesti E., Gori M.C., Ceccanti M., Cambieri C., Fabbri A., Frasca V., Inghilleri M.
    doi: 10.11138/FNeur/2017.32.1.035
  7. A retrospective analysis of 254 acute stroke cases admitted to two university hospitals in Beirut: classification and associated factors
    Lahoud N., Abbas M.-H., Salameh P., Saleh N., Abes S., Hosseini H., Gebeily S.
    doi: 10.11138/FNeur/2017.32.1.041
  8. A 15-year epileptogenic period after perinatal brain injury
    Pisani F., Pavlidis E., Facini C., La Morgia C., Fusco C., Cantalupo G.
    doi: 10.11138/FNeur/2017.32.1.049
  9. In the face of pain there are no heroes. An open letter to the members of the European Parliament about ensuring in the whole Europe high quality care, research, equitable employment opportunities, and socio-economic support for Cluster Headache (CH) pati
    Rossi P., Craven A., De La Torra E.R.
Last Viewed articles: la lista degli ultimi x visitati.
  1. Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study
    Thonnard M., Gosseries O., Demertzi A., Lugo Z., Vanhaudenhuyse A., Bruno M.A., Chatelle C., Thibaut A., Charland-Verville V., Habbal D., Schnakers C., Laureys S.
    doi: 10.11138/FNeur/2013.28.4.259
credits